Treats vernal keratoconjunctivitis (VKC). NDA 214965, held by Harrow Eye. Cyclosporine.
As of Nov 13, 2026, NDA 214965 (Verkazia), held by Harrow Eye, was first approved by FDA on Jun 23, 2021, with 0 approved supplements and 0 published complete response letters.
Verkazia ophthalmic emulsion is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 23, 2021 | Original applicationNew formulation or manufacturer · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Verkazia0.1% · emulsion;ophthalmic | Cyclosporine | RxReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
